On February 17, 2022 Orion’s collaboration partner Bayer reported that has upgraded estimate on Nubeqa’s (darolutamide) peak sales potential (Press release, Orion Biotechnology, FEB 17, 2022, View Source;s%20collaboration%20partner%20Bayer%20has,could%20exceed%20EUR%201%20billion. [SID1234608322]). According to Bayer’s new estimate, Nubeqa’s annual global peak sales could exceed EUR 3 billion . Earlier Bayer has anticipated that Nubeqa’s annual global peak sales could exceed EUR 1 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bayer holds global commercial rights to darolutamide and Orion is entitled to receive annually tiered royalties on global darolutamide sales. The total annual royalty rate is approximately 20% including product sales to Bayer. Initially the total annual royalty rate will be slightly lower, and as sales increase, the total annual royalty rate will increase. Orion manufactures the product for global markets and co-promotes the product in Europe with Bayer.

In addition to royalties, Orion is entitled to receive progressive one-off milestone payments from Bayer that may total EUR 280 million, depending on the future sales development of Nubeqa.